Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1

BackgroundAntigenic chimeric viruses have previously been generated in which the structural genes of recombinant dengue virus type 4 (rDEN4) have been replaced with those derived from DEN2 or DEN3. Two vaccine candidates were identified, rDEN2/4Δ30(ME) and rDEN3/4Δ30(ME), which contain the membrane (M) precursor and envelope (E) genes of DEN2 and DEN3, respectively, and a 30 nucleotide deletion (Δ30) in the 3' untranslated region of the DEN4 backbone. Based on the promising preclinical phenotypes of these viruses and the safety and immunogenicity of rDEN2/4Δ30(ME) in humans, we now describe the generation of a panel of four antigenic chimeric DEN4 viruses using either the capsid (C), M, and E (CME) or ME structural genes of DEN1 Puerto Rico/94 strain.ResultsFour antigenic chimeric viruses were generated and found to replicate efficiently in Vero cells: rDEN1/4(CME), rDEN1/4Δ30(CME), rDEN1/4(ME), and rDEN1/4Δ30(ME). With the exception of rDEN1/4(ME), each chimeric virus was significantly attenuated in a SCID-HuH-7 mouse xenograft model with a 25-fold or greater reduction in replication compared to wild type DEN1. In rhesus monkeys, only chimeric viruses with the Δ30 mutation appeared to be attenuated as measured by duration and magnitude of viremia. rDEN1/4Δ30(CME) appeared over-attenuated since it failed to induce detectable neutralizing antibody and did not confer protection from wild type DEN1 challenge. In contrast, rDEN1/4Δ30(ME) induced 66% seroconversion and protection from DEN1 challenge. Presence of the Δ30 mutation conferred a significant restriction in mosquito infectivity upon rDEN1/4Δ30(ME) which was shown to be non-infectious for Aedes aegypti fed an infectious bloodmeal.ConclusionThe attenuation phenotype in SCID-HuH-7 mice, rhesus monkeys, and mosquitoes and the protective immunity observed in rhesus monkeys suggest that rDEN1/4Δ30(ME) should be considered for evaluation in a clinical trial.

[1]  M. Bray,et al.  Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Charles M. Rice,et al.  Flaviviridae :T he Viruses and Their Replication , 2007 .

[3]  B. Murphy,et al.  Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. , 2003, Vaccine.

[4]  D. Vaughn,et al.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. , 2001, The American journal of tropical medicine and hygiene.

[5]  R. Karron,et al.  A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. , 2001, The American journal of tropical medicine and hygiene.

[6]  B. Murphy,et al.  Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 , 2004, BMC infectious diseases.

[7]  D. Gubler,et al.  Impact of dengue/dengue hemorrhagic fever on the developing world. , 1999, Advances in virus research.

[8]  D. Vaughn,et al.  Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. , 2001, Vaccine.

[9]  B. Murphy,et al.  The Live Attenuated Dengue Serotype 1 Vaccine rDEN1Δ30 is Safe and Highly Immunogenic in Healthy Adult Volunteers , 2006, Human vaccines.

[10]  A. Barrett,et al.  Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys , 2000, Journal of Virology.

[11]  W. Wold,et al.  Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice. , 2006, The Journal of general virology.

[12]  R. Karron,et al.  rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers , 2005 .

[13]  R. Edelman,et al.  Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. , 2003, The American journal of tropical medicine and hygiene.

[14]  B. Murphy,et al.  Genetically modified, live attenuated dengue virus type 3 vaccine candidates. , 2004, The American journal of tropical medicine and hygiene.

[15]  T. Ishikawa,et al.  Flaviviruses , 2005, Perspectives in Medical Virology.

[16]  E. G. Westaway,et al.  RNA binding properties of core protein of the flavivirus Kunjin , 2005, Archives of Virology.

[17]  S. Green,et al.  A live, attenuated recombinant West Nile virus vaccine. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Prata.  Yellow fever. , 2000, Memorias do Instituto Oswaldo Cruz.

[19]  C. Huang,et al.  Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development , 2003, Journal of Virology.

[20]  B. Murphy,et al.  rDEN2/4Δ30(ME), a Live Attenuated Chimeric Dengue Serotype 2 Vaccine, is Safe and Highly Immunogenic in Healthy Dengue-Naïve Adults , 2006, Human vaccines.

[21]  M. Bray,et al.  Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Gubler,et al.  Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses , 2004, Nature Medicine.

[23]  B. Murphy,et al.  A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3′ Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys , 2003, Journal of Virology.

[24]  G. Crane.  Dengue haemorrhagic fever: diagnosis, treatment, prevention and control , 1999 .

[25]  B. Murphy,et al.  Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. , 2003, Vaccine.

[26]  F. Guirakhoo,et al.  Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All , 2006, Human vaccines.

[27]  B. Murphy,et al.  Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. , 2002, Virology.

[28]  Brian R. Murphy,et al.  Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys , 2005, Journal of Virology.

[29]  B. Murphy,et al.  Development of a live attenuated dengue virus vaccine using reverse genetics. , 2006, Viral immunology.

[30]  B. Murphy,et al.  Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. , 2006, Vaccine.

[31]  A. Pletnev,et al.  Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  B. Murphy,et al.  Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. , 2004, Vaccine.

[33]  F. Guirakhoo,et al.  Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates , 2000, Journal of Virology.